Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Entering uncharted waters

Boehringer Ingelheim must have liked what it has seen under a deal signed with Ablynx N.V. earlier this year, as it just entered into a broader deal covering 10 targets. The deal is the first under which Ablynx is developing its nanobodies against targets that haven't yet been clinically validated.

"While the money that we have spent and

Read the full 587 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers